This post uses hypothetical scenarios for illustrative purposes only. It does not describe any actual client, transaction, or representation, and is not legal advice.
Consider a hypothetical founder selling his Tampa services company to a private equity platform. The consideration stack is standard for 2026: 70 percent cash, 20 percent rollover units in the buyer’s holdco, and a seller note for the rest. Everyone in the room thinks of this as M&A consideration. Securities law thinks of it differently. The rollover units are equity securities being offered and sold to the founder. The seller note is, in most framings, a security too. That means two bodies of law have something to say before the founder signs: the federal Securities Act, and — the one that actually gets overlooked — Chapter 517, the Florida Securities and Investor Protection Act, which was rewritten effective October 1, 2024, in ways deal lawyers are still absorbing.
Why the state layer still matters after Reg D
In the standard case, the buyer’s counsel papers the rollover under federal Rule 506(b) of Regulation D, the founder signs an accredited investor questionnaire, and federal preemption does most of the state-law work — securities sold in a compliant 506 offering are federal covered securities, and states are limited to notice filings and fees. If every deal ran that way, Chapter 517 would be a footnote. Deals do not all run that way. Some buyers rely on bare section 4(a)(2) without Reg D, especially in single-seller transactions where nobody wants Form D on EDGAR. Stock-for-stock combinations, earnouts payable in equity, warrant kickers attached to seller notes, and management incentive units issued at closing each raise their own exemption questions. When there is no federal covered security, the offer and sale into or from Florida needs its own Florida exemption, and the burden of proving entitlement to any 517.061 exemption sits, by the statute’s own terms, on the person claiming it.
The 2024 rewrite, chapter 2024-168, reorganized and renumbered the exemption menu in section 517.061, so citations in older deal checklists are now unreliable. The exemptions remain self-executing — no filing required before claiming them — with one deliberate exception discussed below. And everything remains subject to section 517.301: exemption from registration is never exemption from antifraud liability, which is why the disclosure package accompanying a rollover matters even in an exempt deal.
The M&A-relevant exemptions, in the order deal lawyers reach for them
First, the reorganization exemption in subsection (6) covers the distribution of an issuer’s securities to the security holders of another person in connection with a merger, consolidation, exchange of securities, sale of assets, or other reorganization to which both sides (or their parents or subsidiaries) are parties. That is the natural home for stock-for-stock mergers and for holdco equity issued to a target’s shareholders in a rollover structured through an F-reorganization. Its language rewards a careful read in edge cases — a rollover issued to a single founder as negotiated consideration under a purchase agreement is usually within the concept, but counsel should confirm the transaction fits the enumerated forms rather than assuming.
Second, the institutional exemption in subsection (9) handles sales to banks, insurance companies, registered dealers, investment companies, pension trusts, and qualified institutional buyers — the exemption doing the work when the seller of paper is an entity of that class, or when a sponsor syndicates the note to institutions.
Third, the limited offering exemption in subsection (10) — the old workhorse for small private placements — permits sales by an issuer to no more than 35 purchasers in Florida in any consecutive 12-month period, with no general solicitation, and with each purchaser given full and fair disclosure of all material information before sale. Two features deserve flags. Accredited investors are excluded from the 35-purchaser count under paragraph (10)(b), so a deal team issuing rollover units to a handful of accredited founders plus incentive equity to a broader management group has more headroom than the raw number suggests. And the exemption carries a trap built into its own disclosure requirement: every sale under subsection (10) is voidable by the purchaser for three days after first tender of consideration, and the required disclosure must include written notification of that right. A rollover package that omits the three-day rescission notice is not a compliant (10) offering. That notice belongs in the subscription documents as boilerplate, and its absence is the kind of foot fault that surfaces two years later when a disappointed seller’s counsel goes looking for a rescission theory.
Fourth, the accredited-only exemption in subsection (11) — Florida’s analog to solicitation-friendly federal offerings — permits sales exclusively to accredited investors, tolerates a limited general announcement, and is the one exemption that is not self-executing: paragraph (11)(f) requires the issuer to file a notice of transaction, a consent to service of process, and a copy of any general announcement with the Office of Financial Regulation within 15 days after the first sale in Florida. Miss the filing and the exemption’s terms have not been met.
Finally, the 2024 act added something with real diligence consequences: a bad actor disqualification, new section 517.0616, importing the federal Rule 506(d) disqualification standards into the private placement exemptions, including subsections (9), (10), and (11). An issuer with a disqualified covered person — a principal with the wrong regulatory history — cannot claim those exemptions. Buyers’ counsel now needs bad-actor representations for Florida law reasons, not just federal ones, and sellers receiving rollover equity should understand that the questionnaire traffic runs both directions.
What this means at the term sheet stage
None of this is a reason to fear rollover structures; it is a reason to sequence them. The exemption analysis belongs at the term sheet stage, when the consideration mix is being set, not at closing when the subscription booklet shows up. The questions are mechanical once asked: Is the rollover issued under a compliant Reg D offering, making it a federal covered security? If not, which 517.061 subsection covers each instrument — the units, the note, any warrant or earnout equity? Does the disclosure package include the subsection (10) rescission notice if that exemption is the theory? Is a subsection (11) notice filing calendared? Have bad-actor certifications been collected on both sides? For the founder, there is also a protective flip side: a seller receiving equity in an exempt offering is owed full and fair disclosure, and section 517.301’s antifraud reach — plus rescission remedies elsewhere in the chapter for noncompliant sales — gives a rolled-over founder more leverage after a misrepresentation than most founders realize they have.
The takeaway
Every Florida deal that pays consideration in anything other than cash is a securities offering wearing an M&A costume. The 2024 rewrite of Chapter 517 modernized the exemption menu, renumbered it out from under older checklists, imposed a 15-day filing on the accredited-only exemption, wired a three-day rescission right into the limited offering exemption’s disclosure requirements, and bolted on a federal-style bad actor rule. All of it is manageable — most deals fit comfortably within subsection (6) or Reg D preemption — but only if someone runs the analysis instrument by instrument. A disciplined M&A process treats the securities-law workstream as part of structuring, not paperwork.
If you are negotiating rollover equity or seller paper in a Florida transaction, on either side, feel free to reach out to my firm manager, Magda, at Magda@montague.law, or fill out our contact form. Mention you read this post.
